{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:17:40Z","timestamp":1793506660497,"version":"4.5.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0012956","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000}}],"reference-count":156,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["101063914"],"award-info":[{"award-number":["101063914"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE","doi-asserted-by":"crossref","award":["101080784"],"award-info":[{"award-number":["101080784"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["409278\/2023-8"],"award-info":[{"award-number":["409278\/2023-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["23\/15324-8"],"award-info":[{"award-number":["23\/15324-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec025\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Schistosomiasis is caused by infection with worms of the genus\n                      <jats:italic>Schistosoma<\/jats:italic>\n                      including\n                      <jats:italic>S. mansoni<\/jats:italic>\n                      . Over 200 million people are infected, sterile immunity does not naturally develop, and no vaccine is available. This could be a critical tool to achieve control and elimination. Numerous candidates have been tested in pre-clinical models, but there is not yet an approved vaccine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec026\">\n                    <jats:title>Methodology\/Principal Findings<\/jats:title>\n                    <jats:p>\n                      We conducted a scoping review using a keyword search on Web of Science and a MeSH term search on PubMed. Articles were screened and included if they tested a defined vaccine candidate in a pre-clinical protection assay against\n                      <jats:italic>S. mansoni<\/jats:italic>\n                      between 1994\u20132024. Vaccine formulation, study design, and efficacy parameters from all articles were extracted. This data was summarised graphically, with the influence of different parameters appraised. A total of 141 candidate antigens were tested in 108 articles over the last 30 years, with most antigens tested only once and three (Sm-CatB, Sm-p80, and Sm-14) tested over 20 times. The median protective efficacy against worms was 35%. 10 antigens achieved over 60% efficacy, and only two (Sm-p80 and Sm-CatB) over 90%. Large variations in efficacy were observed with all repeatedly tested antigens, likely attributable to differing formulations and study designs. The effect of these varying parameters on the resultant efficacy was evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec027\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A few vaccine candidates have achieved promising efficacy in pre-clinical studies. Most vaccines tested however have efficacy that falls short of that required for an impactful schistosomiasis vaccine. The diversity in study designs makes comparing vaccine targets a challenge. Use of consistent and optimized vaccine formulation (including adjuvant and platform) and study design parameters is critical to expedite the development of a schistosome vaccine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0012956","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T14:00:37Z","timestamp":1748872837000},"page":"e0012956","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0448-6055","authenticated-orcid":true,"given":"Emma L.","family":"Houlder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Ferreira","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"van Diepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murilo Sena","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Alan","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis H.","family":"Hokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meta","family":"Roestenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried A.M.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"issue":"7","key":"pntd.0012956.ref001","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(06)70521-7","article-title":"Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk","volume":"6","author":"P Steinmann","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"pntd.0012956.ref002","volume-title":"Global report on neglected tropical diseases 2024","author":"Organization WH","year":"2024"},{"issue":"1","key":"pntd.0012956.ref003","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/tropicalmed4010040","article-title":"Asian schistosomiasis: current status and prospects for control leading to elimination","volume":"4","author":"CA Gordon","year":"2019","journal-title":"Trop Med Infect Dis"},{"issue":"9936","key":"pntd.0012956.ref004","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(13)61949-2","article-title":"Human schistosomiasis","volume":"383","author":"DG Colley","year":"2014","journal-title":"Lancet"},{"key":"pntd.0012956.ref005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/RRTM.S204345","article-title":"Schistosomiasis: still a cause of significant morbidity and mortality","volume":"10","author":"MA Verjee","year":"2020","journal-title":"Research and Reports in Tropical Medicine"},{"key":"pntd.0012956.ref006","volume-title":"WHO guideline on control and elimination of human schistosomiasis","author":"Organisation WH","year":"2022"},{"issue":"1","key":"pntd.0012956.ref007","first-page":"49","article-title":"Praziquantel as the preferred treatment for schistosomiasis","volume":"75","author":"YH Condeng","year":"2024","journal-title":"Int Marit Health"},{"issue":"12","key":"pntd.0012956.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243224","article-title":"A systematic review and meta-analysis on the rate of human schistosomiasis reinfection","volume":"15","author":"A Zacharia","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"pntd.0012956.ref009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02582-16","article-title":"Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance","volume":"61","author":"N Vale","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"pntd.0012956.ref010","article-title":"The epidemiology of periportal fibrosis and relevance of current Schistosoma mansoni infection: a population-based, cross-sectional study","author":"S Anjorin","year":"2023","journal-title":"medRxiv"},{"key":"pntd.0012956.ref011","article-title":"Concomitant immunity and worm senescence may drive schistosomiasis epidemiological patterns: an eco-evolutionary perspective","volume":"11","author":"JC Buck","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"pntd.0012956.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009946","article-title":"What is the impact of acquired immunity on the transmission of schistosomiasis and the efficacy of current and planned mass drug administration programmes?","volume":"15","author":"K Kura","year":"2021","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"pntd.0012956.ref013","author":"Health IG"},{"issue":"3","key":"pntd.0012956.ref014","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/tropicalmed8030170","article-title":"Human schistosomiasis vaccines as next generation control tools","volume":"8","author":"PJ Hotez","year":"2023","journal-title":"Trop Med Infect Dis"},{"issue":"10","key":"pntd.0012956.ref015","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12101215","article-title":"Models of protective immunity against schistosomes: implications for vaccine development","volume":"12","author":"RA Wilson","year":"2023","journal-title":"Pathogens"},{"issue":"12","key":"pntd.0012956.ref016","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1017\/S0031182009005848","article-title":"Radiation-attenuated schistosome vaccination--a brief historical perspective","volume":"136","author":"QD Bickle","year":"2009","journal-title":"Parasitology"},{"key":"pntd.0012956.ref017","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-3024.2005.00764.x","article-title":"Immunity induced by the radiation-attenuated schistosome vaccine","volume":"27","author":"JP Hewitson","year":"2005","journal-title":"Parasite Immunol"},{"key":"pntd.0012956.ref018","doi-asserted-by":"crossref","DOI":"10.1016\/j.parepi.2020.e00176","article-title":"Current status and future prospects of protein vaccine candidates against Schistosoma mansoni infection","volume":"11","author":"T Eyayu","year":"2020","journal-title":"Parasite Epidemiol Control"},{"issue":"2","key":"pntd.0012956.ref019","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s12639-021-01387-w","article-title":"A comprehensive and critical overview of schistosomiasis vaccine candidates","volume":"45","author":"A Al-Naseri","year":"2021","journal-title":"J Parasit Dis"},{"issue":"3","key":"pntd.0012956.ref020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004033","article-title":"An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas","volume":"10","author":"S Gaze","year":"2014","journal-title":"PLoS Pathog"},{"key":"pntd.0012956.ref021","author":"NIAID","year":"2022"},{"key":"pntd.0012956.ref022","unstructured":"Bottazzi ME. A phase I\/II trial of the safety, immunogenicity, and efficacy of the Sm-TSP-2\/Alhydrogel schistosomiasis vaccine in healthy exposed Ugandan adults. 2022."},{"issue":"3","key":"pntd.0012956.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011236","article-title":"A randomized, controlled Phase 1b trial of the Sm-TSP-2 vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area","volume":"17","author":"DJ Diemert","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0012956.ref024","unstructured":"Tendler M, Diop M, Riveau G, Schacht AM. Sm14 in combination with the adjuvant glucopyranosyl lipid A (GLA-SE) in adults living in endemic regions for S. mansoni and S. haematobium in Senegal, a comparative, randomized, open-label trial. 2017."},{"issue":"12","key":"pntd.0012956.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006968","article-title":"Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: A phase 3 randomized, controlled trial in Senegalese children","volume":"12","author":"G Riveau","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0012956.ref026","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/vaccines9080872","article-title":"The search for a schistosomiasis vaccine: australia\u2019s contribution","volume":"9","author":"DP McManus","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"pntd.0012956.ref027","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23042255","article-title":"Vaccines for human schistosomiasis: recent progress, new developments and future prospects","volume":"23","author":"AJ Molehin","year":"2022","journal-title":"Int J Mol Sci"},{"key":"pntd.0012956.ref028","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S0264-410X(98)00391-0","article-title":"Recombinant vaccinia viruses and gene gun vectors expressing the large subunit of Schistosoma mansoni calpain used in a murine immunization-challenge model","volume":"17","author":"S Hota-Mitchell","year":"1999","journal-title":"Vaccine"},{"issue":"1","key":"pntd.0012956.ref029","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0264-410X(03)00535-8","article-title":"Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu\/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes","volume":"22","author":"KA Shalaby","year":"2003","journal-title":"Vaccine"},{"issue":"1","key":"pntd.0012956.ref030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085401","article-title":"Cysteine peptidases as schistosomiasis vaccines with inbuilt adjuvanticity","volume":"9","author":"R El Ridi","year":"2014","journal-title":"PLoS One"},{"key":"pntd.0012956.ref031","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.molbiopara.2016.11.005","article-title":"WormBase ParaSite - a comprehensive resource for helminth genomics","volume":"215","author":"KL Howe","year":"2017","journal-title":"Mol Biochem Parasitol"},{"issue":"1","key":"pntd.0012956.ref032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001455","article-title":"A systematically improved high quality genome and transcriptome of the human blood fluke Schistosoma mansoni","volume":"6","author":"AV Protasio","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"pntd.0012956.ref033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2010.02.2266","article-title":"Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice","volume":"14","author":"G Ahmad","year":"2010","journal-title":"Int J Infect Dis"},{"issue":"2","key":"pntd.0012956.ref034","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.actatropica.2011.01.010","article-title":"Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum)","volume":"118","author":"W Zhang","year":"2011","journal-title":"Acta Trop"},{"issue":"10","key":"pntd.0012956.ref035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000308","article-title":"Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection","volume":"2","author":"FC Cardoso","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0012956.ref036","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.actatropica.2005.05.007","article-title":"Oral administration of a live Aro attenuated Salmonella vaccine strain expressing 14-kDa Schistosoma mansoni fatty acid-binding protein induced partial protection against experimental schistosomiasis","volume":"95","author":"LGC Pacheco","year":"2005","journal-title":"Acta Trop"},{"issue":"07","key":"pntd.0012956.ref037","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4236\/ojs.2015.57075","article-title":"Variance inflation factor: as a condition for the inclusion of suppressor variable(s) in regression analysis","volume":"05","author":"MO Akinwande","year":"2015","journal-title":"OJS"},{"key":"pntd.0012956.ref038","doi-asserted-by":"crossref","unstructured":"Seabold S, Perktold J. Statsmodels: Econometric and Statistical Modeling with Python. In: Proc of the 9th Python in Science Conf (SciPy 2010), 2010.","DOI":"10.25080\/Majora-92bf1922-011"},{"key":"pntd.0012956.ref039","doi-asserted-by":"crossref","first-page":"159","DOI":"10.12688\/wellcomeopenres.15487.1","article-title":"Systematic screening of 96 Schistosoma mansoni cell-surface and secreted antigens does not identify any strongly protective vaccine candidates in a mouse model of infection","volume":"4","author":"C Crosnier","year":"2019","journal-title":"Wellcome Open Res"},{"issue":"6","key":"pntd.0012956.ref040","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1128\/IAI.72.6.3336-3343.2004","article-title":"Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge","volume":"72","author":"PB Varaldo","year":"2004","journal-title":"Infect Immun"},{"key":"pntd.0012956.ref041","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.vaccine.2003.07.010","article-title":"IL-12 enhances protective immunity in mice engendered by immunization with recombinant 14\u2009kDa Schistosoma mansoni fatty acid-binding protein through an IFN-gamma and TNF-alpha dependent pathway","volume":"22","author":"CT Fonseca","year":"2004","journal-title":"Vaccine"},{"issue":"1","key":"pntd.0012956.ref042","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1574-695X.2006.00133.x","article-title":"Mycobacterial codon optimization of the gene encoding the Sm14 antigen of Schistosoma mansoni in recombinant Mycobacterium bovis Bacille Calmette-Gu\u00e9rin enhances protein expression but not protection against cercarial challenge in mice","volume":"48","author":"PB Varaldo","year":"2006","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"1","key":"pntd.0012956.ref043","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0264-410X(03)00300-1","article-title":"An experimental bivalent peptide vaccine against schistosomiasis and fascioliasis","volume":"22","author":"MM Vilar","year":"2003","journal-title":"Vaccine"},{"issue":"1","key":"pntd.0012956.ref044","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1073\/pnas.93.1.269","article-title":"A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine","volume":"93","author":"M Tendler","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pntd.0012956.ref045","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.actatropica.2008.03.003","article-title":"Peptides containing T cell epitopes, derived from Sm14, but not from paramyosin, induce a Th1 type of immune response, reduction in liver pathology and partial protection against Schistosoma mansoni infection in mice","volume":"106","author":"TCM Garcia","year":"2008","journal-title":"Acta Trop"},{"key":"pntd.0012956.ref046","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1471-2334-14-263","article-title":"Combined immunization using DNA-Sm14 and DNA-Hsp65 increases CD8+ memory T cells, reduces chronic pathology and decreases egg viability during Schistosoma mansoni infection","volume":"14","author":"MS Esp\u00edndola","year":"2014","journal-title":"BMC Infect Dis"},{"key":"pntd.0012956.ref047","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.micinf.2006.06.008","article-title":"Co-administration of plasmid expressing IL-12 with 14-kDa Schistosoma mansoni fatty acid-binding protein cDNA alters immune response profiles and fails to enhance protection induced by Sm14 DNA vaccine alone","volume":"8","author":"CT Fonseca","year":"2006","journal-title":"Microbes Infect"},{"issue":"1","key":"pntd.0012956.ref048","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1590\/S0037-86822002000100003","article-title":"The effects of immunization with recombinant Sm14 (rSm14) in reducing worm burden and mortality of mice infected with Schistosoma mansoni","volume":"35","author":"F Ribeiro","year":"2002","journal-title":"Rev Soc Bras Med Trop"},{"key":"pntd.0012956.ref049","doi-asserted-by":"crossref","first-page":"102446","DOI":"10.1016\/j.parint.2021.102446","article-title":"Increased immunogenicity and protection of recombinant Sm14 antigens by heat-killed Cutibacterium acnes in BALB\/c mice infected with Schistosoma mansoni","volume":"86","author":"HYP Lam","year":"2022","journal-title":"Parasitol Int"},{"key":"pntd.0012956.ref050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.exppara.2014.07.010","article-title":"Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection","volume":"145","author":"RE Ewaisha","year":"2014","journal-title":"Exp Parasitol"},{"key":"pntd.0012956.ref051","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12879-015-0906-z","article-title":"Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model","volume":"15","author":"SF Mossallam","year":"2015","journal-title":"BMC Infect Dis"},{"key":"pntd.0012956.ref052","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1590\/S0074-02762001000900019","article-title":"r-Sm14 - pRSETA efficacy in experimental animals","author":"CR Ramos","year":"2001","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"4","key":"pntd.0012956.ref053","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bbapap.2008.12.010","article-title":"Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: structural and functional characterization of a vaccine candidate","volume":"1794","author":"CRR Ramos","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"pntd.0012956.ref054","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.parint.2008.04.010","article-title":"Oral immunization with Salmonella harboring a Sm14-based DNA vaccine does not protect mice against Schistosoma mansoni infection","volume":"57","author":"LGC Pacheco","year":"2008","journal-title":"Parasitol Int"},{"key":"pntd.0012956.ref055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.exppara.2018.09.018","article-title":"DNA vaccination using recombinant Schistosoma mansoni fatty acid binding protein (smFABP) gene","volume":"194","author":"I Aly","year":"2018","journal-title":"Exp Parasitol"},{"issue":"8","key":"pntd.0012956.ref056","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/jim-2018-000786","article-title":"Schistosoma mansoni antigen Sm-p80: prophylactic efficacy using TLR4 agonist vaccine adjuvant glucopyranosyl lipid A-Alum in murine and non-human primate models","volume":"66","author":"W Zhang","year":"2018","journal-title":"J Investig Med"},{"issue":"15","key":"pntd.0012956.ref057","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/S0264-410X(97)00081-9","article-title":"Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain","volume":"15","author":"S Hota-Mitchell","year":"1997","journal-title":"Vaccine"},{"issue":"9","key":"pntd.0012956.ref058","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/infdis\/jir545","article-title":"Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic","volume":"204","author":"G Ahmad","year":"2011","journal-title":"J Infect Dis"},{"issue":"6","key":"pntd.0012956.ref059","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00436-009-1646-z","article-title":"Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine","volume":"105","author":"G Ahmad","year":"2009","journal-title":"Parasitol Res"},{"issue":"3","key":"pntd.0012956.ref060","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00436-014-3757-4","article-title":"Simultaneous priming with DNA encoding Sm-p80 and boosting with Sm-p80 protein confers protection against challenge infection with Schistosoma mansoni in mice","volume":"113","author":"L Le","year":"2014","journal-title":"Parasitol Res"},{"issue":"4","key":"pntd.0012956.ref061","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.pathol.2018.01.004","article-title":"Schistosoma egg-induced liver pathology resolution by Sm-p80-based schistosomiasis vaccine in baboons","volume":"50","author":"L Le","year":"2018","journal-title":"Pathology"},{"issue":"1","key":"pntd.0012956.ref062","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/nyas.13942","article-title":"Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy","volume":"1425","author":"W Zhang","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"pntd.0012956.ref063","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1128\/IAI.71.7.3844-3851.2003","article-title":"Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4","volume":"71","author":"AA Siddiqui","year":"2003","journal-title":"Infect Immun"},{"key":"pntd.0012956.ref064","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/S0264-410X(03)00159-2","article-title":"Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation","volume":"21","author":"AA Siddiqui","year":"2003","journal-title":"Vaccine"},{"issue":"9","key":"pntd.0012956.ref065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2010.02.2266","article-title":"Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice","volume":"14","author":"G Ahmad","year":"2010","journal-title":"Int J Infect Dis"},{"issue":"3","key":"pntd.0012956.ref066","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-3024.2008.01091.x","article-title":"Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni","volume":"31","author":"G Ahmad","year":"2009","journal-title":"Parasite Immunol"},{"issue":"21","key":"pntd.0012956.ref067","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1016\/j.vaccine.2009.02.096","article-title":"Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model","volume":"27","author":"G Ahmad","year":"2009","journal-title":"Vaccine"},{"issue":"4","key":"pntd.0012956.ref068","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-3024.2009.01181.x","article-title":"Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse","volume":"32","author":"W Zhang","year":"2010","journal-title":"Parasite Immunol"},{"issue":"7","key":"pntd.0012956.ref069","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1086\/651147","article-title":"Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine","volume":"201","author":"W Zhang","year":"2010","journal-title":"J Infect Dis"},{"key":"pntd.0012956.ref070","doi-asserted-by":"crossref","first-page":"605288","DOI":"10.3389\/fimmu.2020.605288","article-title":"Adjuvanted Schistosoma mansoni-Cathepsin B with sulfated lactosyl archaeol archaeosomes or AddaVax provides protection in a pre-clinical schistosomiasis model","volume":"11","author":"DJ Perera","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"pntd.0012956.ref071","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.vaccine.2014.11.016","article-title":"Evaluation of the immune response and protective efficacy of Schistosoma mansoni Cathepsin B in mice using CpG dinucleotides as adjuvant","volume":"33","author":"A Ricciardi","year":"2015","journal-title":"Vaccine"},{"key":"pntd.0012956.ref072","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12879-016-1444-z","article-title":"A vaccine consisting of Schistosoma mansoni cathepsin B formulated in Montanide ISA 720 VG induces high level protection against murine schistosomiasis","volume":"16","author":"A Ricciardi","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"3","key":"pntd.0012956.ref073","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005443","article-title":"Protective immune responses against Schistosoma mansoni infection by immunization with functionally active gut-derived cysteine peptidases alone and in combination with glyceraldehyde 3-phosphate dehydrogenase","volume":"11","author":"H Tallima","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0012956.ref074","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41541-023-00599-w","article-title":"Salmonella Typhimurium expressing chromosomally integrated Schistosoma mansoni Cathepsin B protects against schistosomiasis in mice","volume":"8","author":"AS Hassan","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"39","key":"pntd.0012956.ref075","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1016\/j.vaccine.2021.08.031","article-title":"Therapeutic activity of a Salmonella-vectored Schistosoma mansoni vaccine in a mouse model of chronic infection","volume":"39","author":"AS Hassan","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"pntd.0012956.ref076","article-title":"Specific antibodies and arachidonic acid mediate the protection induced by the Schistosoma mansoni cysteine peptidase-based vaccine in mice","volume":"8","author":"H Tallima","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"pntd.0012956.ref077","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007490","article-title":"Vaccination against the digestive enzyme Cathepsin B using a YS1646 Salmonella enterica Typhimurium vector provides almost complete protection against Schistosoma mansoni challenge in a mouse model","volume":"13","author":"AS Hassan","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0012956.ref078","doi-asserted-by":"crossref","first-page":"104036","DOI":"10.1016\/j.ebiom.2022.104036","article-title":"A low dose adenovirus vectored vaccine expressing Schistosoma mansoni Cathepsin B protects from intestinal schistosomiasis in mice","volume":"80","author":"DJ Perera","year":"2022","journal-title":"EBioMedicine"},{"issue":"7","key":"pntd.0012956.ref079","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/pim.12118","article-title":"A multivalent chimeric vaccine composed of Schistosoma mansoni SmTSP-2 and Sm29 was able to induce protection against infection in mice","volume":"36","author":"CS Pinheiro","year":"2014","journal-title":"Parasite Immunol"},{"issue":"2","key":"pntd.0012956.ref080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003537","article-title":"Sm29, but not Sm22.6 retains its ability to induce a protective immune response in mice previously exposed to a Schistosoma mansoni infection","volume":"9","author":"CC Alves","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0012956.ref081","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jconrel.2018.02.004","article-title":"The use of gold nanorods as a new vaccine platform against schistosomiasis","volume":"275","author":"NRG Assis","year":"2018","journal-title":"J Control Release"},{"issue":"5","key":"pntd.0012956.ref082","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125075","article-title":"DNA vaccine encoding the chimeric form of Schistosoma mansoni Sm-TSP2 and Sm29 confers partial protection against challenge infection","volume":"10","author":"NR Gon\u00e7alves de Assis","year":"2015","journal-title":"PLoS One"},{"issue":"16","key":"pntd.0012956.ref083","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/0161-5890(94)90075-2","article-title":"Evaluation of the effect of Sm28GST-derived peptides in murine hepatosplenic schistosomiasis: interest of the lipopeptidic form of the C-terminal peptide","volume":"31","author":"V Pancr\u00e9","year":"1994","journal-title":"Mol Immunol"},{"issue":"4","key":"pntd.0012956.ref084","first-page":"536","article-title":"Expression of a 28-kilodalton glutathione S-transferase antigen of Schistosoma mansoni on the surface of filamentous phages and evaluation of its vaccine potential","volume":"10","author":"KV Rao","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"issue":"5","key":"pntd.0012956.ref085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.imbio.2007.10.002","article-title":"Protective effect and granuloma down-modulation promoted by RP44 antigen a fructose 1,6 bisphosphate aldolase of Schistosoma mansoni","volume":"213","author":"HH Marques","year":"2008","journal-title":"Immunobiology"},{"issue":"2","key":"pntd.0012956.ref086","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4049\/jimmunol.163.2.1045","article-title":"Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice","volume":"163","author":"JB Sun","year":"1999","journal-title":"J Immunol"},{"key":"pntd.0012956.ref087","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0264-410X(00)00363-7","article-title":"Immunostimulatory effect of IL-18-encoding plasmid in DNA vaccination against murine Schistosoma mansoni infection","volume":"19","author":"L Dupr\u00e9","year":"2001","journal-title":"Vaccine"},{"issue":"12","key":"pntd.0012956.ref088","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/0264-410X(96)00048-5","article-title":"Mucosal vaccination against schistosomiasis using liposome-associated Sm 28\u2009kDa glutathione S-transferase","volume":"14","author":"N Ivanoff","year":"1996","journal-title":"Vaccine"},{"key":"pntd.0012956.ref089","doi-asserted-by":"crossref","first-page":"106033","DOI":"10.1016\/j.actatropica.2021.106033","article-title":"Heat-killed Propionibacterium acnes augment the protective effect of 28-kDa glutathione S-transferases antigen against Schistosoma mansoni infection","volume":"222","author":"HYP Lam","year":"2021","journal-title":"Acta Trop"},{"key":"pntd.0012956.ref090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-3024.2003.00651.x","article-title":"A DNA-prime\/protein-boost vaccination regimen enhances Th2 immune responses but not protection following Schistosoma mansoni infection","volume":"25","author":"AA Da\u2019Dara","year":"2003","journal-title":"Parasite Immunol"},{"key":"pntd.0012956.ref091","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0264-410X(01)00374-7","article-title":"Immunization with plasmid DNA encoding the integral membrane protein, Sm23, elicits a protective immune response against schistosome infection in mice","volume":"20","author":"AA Da\u2019dara","year":"2001","journal-title":"Vaccine"},{"issue":"4","key":"pntd.0012956.ref092","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-3024.2002.00453.x","article-title":"Comparative efficacy of the Schistosoma mansoni nucleic acid vaccine, Sm23, following microseeding or gene gun delivery","volume":"24","author":"AA Da\u2019dara","year":"2002","journal-title":"Parasite Immunol"},{"issue":"9","key":"pntd.0012956.ref093","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-3024.2005.00785.x","article-title":"Comparison of Schistosoma mansoni irradiated cercariae and Sm23 DNA vaccines","volume":"27","author":"LM Ganley-Leal","year":"2005","journal-title":"Parasite Immunol"},{"issue":"1","key":"pntd.0012956.ref094","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0264-410X(98)00152-2","article-title":"Induction of a protective immunity against Schistosoma mansoni with ovalbumin-coupled Sm37-5 coadsorbed with granulocyte-macrophage colony stimulating factor (GM-CSF) or IL-12 on alum","volume":"17","author":"L Argiro","year":"1999","journal-title":"Vaccine"},{"issue":"19","key":"pntd.0012956.ref095","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/S0264-410X(99)00523-X","article-title":"Induction of a protection against S. mansoni with a MAP containing epitopes of Sm37-GAPDH and Sm10-DLC. Effect of coadsorption with GM-CSF on alum","volume":"18","author":"L Argiro","year":"2000","journal-title":"Vaccine"},{"issue":"19","key":"pntd.0012956.ref096","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0264-410X(99)00521-6","article-title":"Identification of a candidate vaccine peptide on the 37\u2009kDa Schistosoma mansoni GAPDH","volume":"18","author":"LL Argiro","year":"2000","journal-title":"Vaccine"},{"issue":"4","key":"pntd.0012956.ref097","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.0300-9475.2004.01497.x","article-title":"Immunogenicity and vaccine potential of dipeptidic multiple antigen peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase","volume":"60","author":"R El Ridi","year":"2004","journal-title":"Scand J Immunol"},{"key":"pntd.0012956.ref098","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3389\/fimmu.2018.01762","article-title":"Schistosoma mansoni SmKI-1 or its C-terminal fragment induces partial protection against S. mansoni infection in mice","volume":"9","author":"SB Morais","year":"2018","journal-title":"Front Immunol"},{"key":"pntd.0012956.ref099","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02498","article-title":"Peptides derived of Kunitz-type serine protease inhibitor as potential vaccine against experimental schistosomiasis","volume":"10","author":"J Hern\u00e1ndez-Goenaga","year":"2019","journal-title":"Front Immunol"},{"key":"pntd.0012956.ref100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijid.2017.10.024","article-title":"Kunitz-type protease inhibitor as a vaccine candidate against schistosomiasis mansoni","volume":"66","author":"SL Ranasinghe","year":"2018","journal-title":"Int J Infect Dis"},{"issue":"3","key":"pntd.0012956.ref101","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0192-0561(98)00083-6","article-title":"Proteosome delivery of a protective 9B-antigen against Schistosoma mansoni","volume":"21","author":"R Tarrab-Hazdai","year":"1999","journal-title":"Int J Immunopharmacol"},{"issue":"4","key":"pntd.0012956.ref102","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1365-2567.2000.00139.x","article-title":"A mimotope peptide-based vaccine against Schistosoma mansoni: synthesis and characterization","volume":"101","author":"R Arnon","year":"2000","journal-title":"Immunology"},{"issue":"9","key":"pntd.0012956.ref103","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/IAI.67.9.4360-4366.1999","article-title":"Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni","volume":"67","author":"T Ben-Yedidia","year":"1999","journal-title":"Infect Immun"},{"key":"pntd.0012956.ref104","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.exppara.2014.02.003","article-title":"Evaluation of the use of C-terminal part of the Schistosoma mansoni 200kDa tegumental protein in schistosomiasis diagnosis and vaccine formulation","volume":"139","author":"de Carvalho GBF","year":"2014","journal-title":"Exp Parasitol"},{"issue":"1","key":"pntd.0012956.ref105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1590\/S0074-02762007000100003","article-title":"Assessment of a DNA vaccine encoding an anchored-glycosylphosphatidylinositol tegumental antigen complexed to protamine sulphate on immunoprotection against murine schistosomiasis","volume":"102","author":"EJM Nascimento","year":"2007","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"pntd.0012956.ref106","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1590\/S0074-02762006000900060","article-title":"Aluminum hydroxide associated to Schistosoma mansoni 22.6\u2009kDa protein abrogates partial protection against experimental infection but not alter interleukin-10 production","author":"LGG Pac\u00edfico","year":"2006","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"pntd.0012956.ref107","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.imbio.2005.06.004","article-title":"Immunization with Schistosoma mansoni 22.6\u2009kDa antigen induces partial protection against experimental infection in a recombinant protein form but not as DNA vaccine","volume":"211","author":"LGG Pac\u00edfico","year":"2006","journal-title":"Immunobiology"},{"key":"pntd.0012956.ref108","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fimmu.2015.00273","article-title":"Protective potential of antioxidant enzymes as vaccines for schistosomiasis in a non-human primate model","volume":"6","author":"C Carvalho-Queiroz","year":"2015","journal-title":"Front Immunol"},{"issue":"10","key":"pntd.0012956.ref109","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1128\/IAI.72.10.6112-6124.2004","article-title":"Nucleic acid vaccination with Schistosoma mansoni antioxidant enzyme cytosolic superoxide dismutase and the structural protein filamin confers protection against the adult worm stage","volume":"72","author":"RM Cook","year":"2004","journal-title":"Infect Immun"},{"issue":"3","key":"pntd.0012956.ref110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001564","article-title":"Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2","volume":"6","author":"MS Pearson","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"pntd.0012956.ref111","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nm1430","article-title":"Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis","volume":"12","author":"MH Tran","year":"2006","journal-title":"Nat Med"},{"key":"pntd.0012956.ref112","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0264-410X(01)00345-0","article-title":"DNA vaccination with asparaginyl endopeptidase (Sm32) from the parasite Schistosoma mansoni: anti-fecundity effect induced in mice","volume":"20","author":"K Chlichlia","year":"2001","journal-title":"Vaccine"},{"issue":"6","key":"pntd.0012956.ref113","article-title":"Saposin-like proteins are expressed in the gastrodermis of Schistosoma mansoni and are immunogenic in natural infections","volume":"12","author":"TA Don","year":"2008","journal-title":"Int J Infect Dis"},{"issue":"2","key":"pntd.0012956.ref114","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3390\/vaccines8020162","article-title":"Vaccination with schistosoma mansoni cholinesterases reduces the parasite burden and egg viability in a mouse model of schistosomiasis","volume":"8","author":"BA Tedla","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"pntd.0012956.ref115","doi-asserted-by":"crossref","first-page":"105356","DOI":"10.1016\/j.actatropica.2020.105356","article-title":"Recombinant micro-exon gene 3 (MEG-3) antigens from Schistosoma mansoni failed to induce protection against infection but show potential for serological diagnosis","volume":"204","author":"FS Mambelli","year":"2020","journal-title":"Acta Trop"},{"key":"pntd.0012956.ref116","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.58","article-title":"Immunization with tegument nucleotidases associated with a subcurative praziquantel treatment reduces worm burden following Schistosoma mansoni challenge","volume":"1","author":"HK Rofatto","year":"2013","journal-title":"PeerJ"},{"key":"pntd.0012956.ref117","doi-asserted-by":"crossref","first-page":"938457","DOI":"10.1100\/2012\/938457","article-title":"Oral vaccination based on DNA-chitosan nanoparticles against Schistosoma mansoni infection","volume":"2012","author":"CR Oliveira","year":"2012","journal-title":"ScientificWorldJournal"},{"issue":"11","key":"pntd.0012956.ref118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001894","article-title":"A new strategy based on SmRho protein loaded chitosan nanoparticles as a candidate oral vaccine against schistosomiasis","volume":"6","author":"CR Oliveira","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0012956.ref119","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1590\/S0074-02761998000700032","article-title":"Induction of protective immunity against Schistosoma mansoni infection by antigens purified from PIII, a fraction of adult worm, associated to the downregulation of granuloma formation","author":"S Gustavson","year":"1998","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"pntd.0012956.ref120","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13071-016-1500-y","article-title":"Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems","volume":"9","author":"B Vicente","year":"2016","journal-title":"Parasit Vectors"},{"key":"pntd.0012956.ref121","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0264-410X(02)00471-1","article-title":"A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection","volume":"21","author":"M Lebens","year":"2003","journal-title":"Vaccine"},{"issue":"1","key":"pntd.0012956.ref122","doi-asserted-by":"crossref","first-page":"20488","DOI":"10.1038\/s41598-023-47480-3","article-title":"Plant-based production of a protective vaccine antigen against the bovine parasitic nematode Ostertagia ostertagi","volume":"13","author":"L Zwanenburg","year":"2023","journal-title":"Sci Rep"},{"issue":"8","key":"pntd.0012956.ref123","article-title":"Platforms for production of protein-based vaccines: from classical to next-generation strategies","volume":"11","author":"R Cid","year":"2021","journal-title":"Biomolecules"},{"issue":"12","key":"pntd.0012956.ref124","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/infdis\/jiu031","article-title":"Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons","volume":"209","author":"S Karmakar","year":"2014","journal-title":"J Infect Dis"},{"issue":"1","key":"pntd.0012956.ref125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/nyas.13866","article-title":"Sm-p80-based vaccine trial in baboons: efficacy when mimicking natural conditions of chronic disease, praziquantel therapy, immunization, and Schistosoma mansoni re-encounter","volume":"1425","author":"AJ Siddiqui","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"pntd.0012956.ref126","author":"World Health Organization.","year":"2024"},{"key":"pntd.0012956.ref127","unstructured":"PATH. RSV vaccine and mAb snapshot. 2024."},{"issue":"8","key":"pntd.0012956.ref128","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.vaccine.2015.12.032","article-title":"Workshop report: Schistosomiasis vaccine clinical development and product characteristics","volume":"34","author":"AX Mo","year":"2016","journal-title":"Vaccine"},{"key":"pntd.0012956.ref129","article-title":"Vaccine value profile for schistosomiasis","author":"G Yamey","year":"2024","journal-title":"Vaccine"},{"key":"pntd.0012956.ref130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-0716-0635-3_19","article-title":"Testing of Schistosoma mansoni vaccine targets","volume":"2151","author":"W Zhang","year":"2020","journal-title":"Methods Mol Biol"},{"issue":"11","key":"pntd.0012956.ref131","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1073\/pnas.1708274114","article-title":"The preregistration revolution","volume":"115","author":"BA Nosek","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"37","key":"pntd.0012956.ref132","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1016\/j.vaccine.2013.05.026","article-title":"Successful immunization against a parasitic nematode by vaccination with recombinant proteins","volume":"31","author":"AJ Nisbet","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"pntd.0012956.ref133","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00436-023-08016-w","article-title":"Enhanced protective immunity against Baylisascaris schroederi infection in mice through a multi-antigen cocktail vaccine approach","volume":"123","author":"L Xiong","year":"2023","journal-title":"Parasitol Res"},{"issue":"1","key":"pntd.0012956.ref134","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13567-021-00895-0","article-title":"Efficacy of a multivalent vaccine against Fasciola hepatica infection in sheep","volume":"52","author":"R Zafra","year":"2021","journal-title":"Vet Res"},{"issue":"11","key":"pntd.0012956.ref135","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/14760584.2021.1999810","article-title":"Identifying novel candidates and configurations for human helminth vaccines","volume":"20","author":"RM Maizels","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"pntd.0012956.ref136","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molimm.2019.04.021","article-title":"The Schistosoma mansoni cyclophilin A epitope 107-121 induces a protective immune response against schistosomiasis","volume":"111","author":"TT de Melo","year":"2019","journal-title":"Mol Immunol"},{"key":"pntd.0012956.ref137","article-title":"Fifteen years of Sm-p80-based vaccine trials in nonhuman primates: antibodies from vaccinated baboons confer protection in vivo and in vitro from Schistosoma mansoni and identification of putative correlative markers of protection","volume":"11","author":"WD Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"pntd.0012956.ref138","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01710","article-title":"Immune mechanisms involved in cathepsin B vaccine induced protection in mice","volume":"9","author":"A Ricciardi","year":"2018","journal-title":"Front Immunol"},{"issue":"43","key":"pntd.0012956.ref139","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1016\/j.vaccine.2019.08.075","article-title":"A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area","volume":"37","author":"WA Keitel","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"pntd.0012956.ref140","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"S Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"pntd.0012956.ref141","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032700","article-title":"A Comprehensive Review of mRNA Vaccines","volume":"24","author":"V Gote","year":"2023","journal-title":"Int J Mol Sci"},{"key":"pntd.0012956.ref142","doi-asserted-by":"crossref","first-page":"46621","DOI":"10.1038\/srep46621","article-title":"Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine","volume":"7","author":"KA Collins","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"pntd.0012956.ref143","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3390\/vaccines2030654","article-title":"Schistosome Vaccine Adjuvants in Preclinical and Clinical Research","volume":"2","author":"R Stephenson","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"pntd.0012956.ref144","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13071-016-1369-9","article-title":"Do schistosome vaccine trials in mice have an intrinsic flaw that generates spurious protection data?","volume":"9","author":"RA Wilson","year":"2016","journal-title":"Parasit Vectors"},{"issue":"12","key":"pntd.0012956.ref145","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.7326\/M22-2089","article-title":"Safety and immunogenicity of intradermal fractional dose administration of the mRNA-1273 vaccine: a proof-of-concept study","volume":"175","author":"GVT Roozen","year":"2022","journal-title":"Ann Intern Med"},{"issue":"10","key":"pntd.0012956.ref146","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00724-23","article-title":"Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants","volume":"97","author":"M Xing","year":"2023","journal-title":"J Virol"},{"issue":"6","key":"pntd.0012956.ref147","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007349","article-title":"Modelling the impact of a Schistosoma mansoni vaccine and mass drug administration to achieve morbidity control and transmission elimination","volume":"13","author":"K Kura","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0012956.ref148","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13071-017-2227-0","article-title":"Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities","volume":"10","author":"A Stylianou","year":"2017","journal-title":"Parasit Vectors"},{"issue":"1","key":"pntd.0012956.ref149","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/s41467-023-37502-z","article-title":"Pulmonary inflammation promoted by type-2 dendritic cells is a feature of human and murine schistosomiasis","volume":"14","author":"EL Houlder","year":"2023","journal-title":"Nat Commun"},{"key":"pntd.0012956.ref150","doi-asserted-by":"crossref","first-page":"906338","DOI":"10.3389\/fimmu.2022.906338","article-title":"Dynamics of host immune response development during Schistosoma mansoni infection","volume":"13","author":"AH Costain","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"pntd.0012956.ref151","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003805","article-title":"It\u2019s all about those bases: the need for incorporating parasite genetic heterogeneity into the development of schistosome vaccines","volume":"9","author":"AM Gleichsner","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0012956.ref152","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/ph16030334","article-title":"Recent advances in the development of adenovirus-vectored vaccines for parasitic infections","volume":"16","author":"C Koger-Pease","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"pntd.0012956.ref153","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.04.027","article-title":"Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths","volume":"130","author":"DJ Diemert","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"pntd.0012956.ref154","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.vaccine.2009.09.047","article-title":"Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles","volume":"28","author":"BY Lee","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"pntd.0012956.ref155","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41591-020-0759-x","article-title":"A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics","volume":"26","author":"MCC Langenberg","year":"2020","journal-title":"Nat Med"},{"key":"pntd.0012956.ref156","doi-asserted-by":"crossref","first-page":"17","DOI":"10.12688\/aasopenres.12972.1","article-title":"Risk assessment for the implementation of controlled human Schistosoma mansoni infection trials in Uganda","volume":"2","author":"JP Koopman","year":"2019","journal-title":"AAS Open Res"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0012956","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T14:04:34Z","timestamp":1749650674000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012956"}},"subtitle":[],"editor":[{"given":"David J.","family":"Diemert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":156,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0012956","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.03.03.641165","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]}}}